SUBSCRIBE
SUBSCRIBE

AstraZeneca

NEWS
Biotech Beach
The Day In Review: AstraZeneca PLC Enters Two Partnerships
January 31, 2007
 · 
1 min read
Biotech Beach
The Day In Review: Amgen (Jobs) Rises On Speculation Over Patent Suit
January 22, 2007
 · 
1 min read
Biotech Beach
The Day In Review: Bristol-Myers Squibb Company In $1.2 Billion Pact With AstraZeneca PLC
January 11, 2007
 · 
1 min read
Bio NC
The Day In Review: Targacept, Inc. Climbs On AstraZeneca PLC Payment
December 27, 2006
 · 
1 min read
Genetown
1 In 5 Early-Stage Breast Cancer Patients May Not Follow Hormonal Therapy Plan
December 18, 2006
 · 
1 min read
Policy
Out Of REACH: New Legislation Threatens Medicines
November 20, 2006
 · 
1 min read
Genetown
The Day In Review: Cambrex Corporation Sells Bio Businesses For $460 Million
October 24, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Synta Pharmaceuticals Reports Progress Against Melanoma
September 15, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Ligand Pharmaceuticals Inc. Sells Avinza To King Pharmaceuticals®, Inc. For $265 Million
September 7, 2006
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
June 29, 2026
 · 
14 min read
Press Releases
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
June 26, 2026
 · 
10 min read
Press Releases
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026
 · 
7 min read
Press Releases
AstraZeneca Joins ZERO Prostate Cancer’s Historic ‘Blitz the Barriers’ Initiative as a Founding Partner
June 15, 2026
 · 
3 min read
Press Releases
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 14, 2026
 · 
19 min read
Press Releases
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
June 8, 2026
 · 
7 min read
Press Releases
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
June 3, 2026
 · 
4 min read
Press Releases
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
June 1, 2026
 · 
7 min read
Press Releases
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 29, 2026
 · 
19 min read
Press Releases
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 24, 2026
 · 
19 min read
Load More